Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2619779,lag time,"The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),min,16,673,DB00130,L-Glutamine
,2619779,kinv,"The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),1/[h],10,674,DB00130,L-Glutamine
,2619779,Cmax,"The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),[mg] / [l],11.9,675,DB00130,L-Glutamine
,2619779,tmax,"The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),h,2.3,676,DB00130,L-Glutamine
,2619779,mean residence time (MRT),"The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),h,6.9,677,DB00130,L-Glutamine
,2619779,AUC,"The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),,60.6,678,DB00130,L-Glutamine
,2619779,lag time,"After the last dose of 400 mg the lag time was 17 +/- 6 min, the Cmax 12.7 +/- 3.8 mg/l at tmax of 2.1 +/- 0.8 h, a MRT of 11.0 +/- 1.9 h and an AUC of 109.8 +/- 39.9 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),min,17,679,DB00130,L-Glutamine
,2619779,Cmax,"After the last dose of 400 mg the lag time was 17 +/- 6 min, the Cmax 12.7 +/- 3.8 mg/l at tmax of 2.1 +/- 0.8 h, a MRT of 11.0 +/- 1.9 h and an AUC of 109.8 +/- 39.9 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),[mg] / [l],12.7,680,DB00130,L-Glutamine
,2619779,tmax,"After the last dose of 400 mg the lag time was 17 +/- 6 min, the Cmax 12.7 +/- 3.8 mg/l at tmax of 2.1 +/- 0.8 h, a MRT of 11.0 +/- 1.9 h and an AUC of 109.8 +/- 39.9 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),h,2.1,681,DB00130,L-Glutamine
,2619779,MRT,"After the last dose of 400 mg the lag time was 17 +/- 6 min, the Cmax 12.7 +/- 3.8 mg/l at tmax of 2.1 +/- 0.8 h, a MRT of 11.0 +/- 1.9 h and an AUC of 109.8 +/- 39.9 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),h,11.0,682,DB00130,L-Glutamine
,2619779,AUC,"After the last dose of 400 mg the lag time was 17 +/- 6 min, the Cmax 12.7 +/- 3.8 mg/l at tmax of 2.1 +/- 0.8 h, a MRT of 11.0 +/- 1.9 h and an AUC of 109.8 +/- 39.9 (mg/l) x h.",Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619779/),[mg] / [h·l)],109.8,683,DB00130,L-Glutamine
,7751998,dial,"In group 2 (n = 6), peritoneal dialysis and continuous arteriovenous hemodiafiltration (CAVHD) (dialysate flow = 1000 ml.hr-1) were simultaneous performed for 40 minutes.","Use of peritoneal dialysis, continuous arteriovenous hemofiltration, and continuous arteriovenous hemodiafiltration for removal of ammonium chloride and glutamine in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751998/),[ml] / [h],1000,7334,DB00130,L-Glutamine
,7751998,flow,"In group 2 (n = 6), peritoneal dialysis and continuous arteriovenous hemodiafiltration (CAVHD) (dialysate flow = 1000 ml.hr-1) were simultaneous performed for 40 minutes.","Use of peritoneal dialysis, continuous arteriovenous hemofiltration, and continuous arteriovenous hemodiafiltration for removal of ammonium chloride and glutamine in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751998/),[ml] / [h],1000,7335,DB00130,L-Glutamine
,9029053,Liver,"Liver concentrations of 4-ene VPA and alpha-fluoro-4-ene VPA were 0.96 +/- 0.11 and 0.89 +/- 0.19 micromol/g of wet liver, respectively, at 1 hr after the dose.",A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029053/),μ,0.96,9610,DB00130,L-Glutamine
,9029053,Liver,"Liver concentrations of 4-ene VPA and alpha-fluoro-4-ene VPA were 0.96 +/- 0.11 and 0.89 +/- 0.19 micromol/g of wet liver, respectively, at 1 hr after the dose.",A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029053/),μ,0.89,9611,DB00130,L-Glutamine
,22958974,percent recovery,"Mean percent recovery of phenylbutyric acid as urinary phenylacetylglutamine was 66.4 and 69.0 for pediatric patients and 68.7 and 71.4 for adult patients on glycerol phenylbutyrate and sodium phenylbutyrate, respectively.",Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22958974/),,66.4,12843,DB00130,L-Glutamine
,22958974,percent recovery,"Mean percent recovery of phenylbutyric acid as urinary phenylacetylglutamine was 66.4 and 69.0 for pediatric patients and 68.7 and 71.4 for adult patients on glycerol phenylbutyrate and sodium phenylbutyrate, respectively.",Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22958974/),,69.0,12844,DB00130,L-Glutamine
,22958974,percent recovery,"Mean percent recovery of phenylbutyric acid as urinary phenylacetylglutamine was 66.4 and 69.0 for pediatric patients and 68.7 and 71.4 for adult patients on glycerol phenylbutyrate and sodium phenylbutyrate, respectively.",Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22958974/),,68.7,12845,DB00130,L-Glutamine
,22958974,percent recovery,"Mean percent recovery of phenylbutyric acid as urinary phenylacetylglutamine was 66.4 and 69.0 for pediatric patients and 68.7 and 71.4 for adult patients on glycerol phenylbutyrate and sodium phenylbutyrate, respectively.",Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22958974/),,71.4,12846,DB00130,L-Glutamine
,15063465,capacity factor,"The samples were injected onto the analytical column (Tracer Extrasil ODS1) and detected at 238 nm, giving a capacity factor of 1.87 for CR 3210 and 1.10 for the internal standard.",Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),,1.87,13711,DB00130,L-Glutamine
,15063465,capacity factor,"The samples were injected onto the analytical column (Tracer Extrasil ODS1) and detected at 238 nm, giving a capacity factor of 1.87 for CR 3210 and 1.10 for the internal standard.",Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),,1.10,13712,DB00130,L-Glutamine
,15063465,recovery,The mean recovery of CR 3210 from spiked rat plasma was 68.5 at 75 ng/ml and 80.9 at 3000 ng/ml; the mean recovery of CR 3210 from spiked rat urine was 69.9 at 75 ng/ml and 78.6 at 3000 ng/ml.,Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),,68.5,13713,DB00130,L-Glutamine
,15063465,recovery,The mean recovery of CR 3210 from spiked rat plasma was 68.5 at 75 ng/ml and 80.9 at 3000 ng/ml; the mean recovery of CR 3210 from spiked rat urine was 69.9 at 75 ng/ml and 78.6 at 3000 ng/ml.,Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),,80.9,13714,DB00130,L-Glutamine
,15063465,recovery,The mean recovery of CR 3210 from spiked rat plasma was 68.5 at 75 ng/ml and 80.9 at 3000 ng/ml; the mean recovery of CR 3210 from spiked rat urine was 69.9 at 75 ng/ml and 78.6 at 3000 ng/ml.,Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),,69.9,13715,DB00130,L-Glutamine
,15063465,recovery,The mean recovery of CR 3210 from spiked rat plasma was 68.5 at 75 ng/ml and 80.9 at 3000 ng/ml; the mean recovery of CR 3210 from spiked rat urine was 69.9 at 75 ng/ml and 78.6 at 3000 ng/ml.,Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),,78.6,13716,DB00130,L-Glutamine
,15063465,lower limit of detection (LOD),The lower limit of detection (LOD) was 14 ng/ml in plasma and 22 ng/ml in urine samples.,Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),[ng] / [ml],14,13717,DB00130,L-Glutamine
,15063465,lower limit of detection (LOD),The lower limit of detection (LOD) was 14 ng/ml in plasma and 22 ng/ml in urine samples.,Sensitive SPE-HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063465/),[ng] / [ml],22,13718,DB00130,L-Glutamine
,9022538,absorption constant,"OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L].",Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9022538/),1/[min],0.028,15198,DB00130,L-Glutamine
,9022538,elimination half-life,"OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L].",Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9022538/),min,89,15199,DB00130,L-Glutamine
,9022538,area under the curve (AUC)0-7h,"OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L].",Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9022538/),[mM·min] / [l],41.4,15200,DB00130,L-Glutamine
,9022538,area under the curve (AUC)0-7h,"OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L].",Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9022538/),[mM·min] / [l],20.4,15201,DB00130,L-Glutamine
,9022538,area under the curve (AUC)0-7h,"OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L].",Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9022538/),[mM·min] / [l],7.3,15202,DB00130,L-Glutamine
,33388234,plasma ammonia level,Average plasma ammonia level excluding HAC was 94.3 µmol/L at baseline and 50.4 µmol/L at the end of the transition period (p = 0.21).,Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388234/),[μM] / [l],94.3,19481,DB00130,L-Glutamine
,33388234,plasma ammonia level,Average plasma ammonia level excluding HAC was 94.3 µmol/L at baseline and 50.4 µmol/L at the end of the transition period (p = 0.21).,Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388234/),[μM] / [l],50.4,19482,DB00130,L-Glutamine
less,12098087,secondary,Both ReFacto and Octonativ-M7 treatment reduced secondary bleeding time to less than 6 minutes.,Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098087/),min,6,23979,DB00130,L-Glutamine
,29902908,t1/2α,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),h,0.139,27220,DB00130,L-Glutamine
,29902908,Vd2,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),h·l⁻¹·mg,133.335,27221,DB00130,L-Glutamine
,29902908,Vd2,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),h·l⁻¹·mg,143.851,27222,DB00130,L-Glutamine
,29902908,Vd2,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),h·l⁻¹·mg,14.464,27223,DB00130,L-Glutamine
,29902908,Vd2,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),kg⁻¹·l,0.009,27224,DB00130,L-Glutamine
,29902908,Vd2,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),kg⁻¹·l,0.223,27225,DB00130,L-Glutamine
,29902908,Vd2,"The main pharmacokinetics parameters of t1/2α, t1/2β, CL₁, CL₂, AUC0-t, AUC0-∞, Vd1, and Vd2 were (0.139±0.007) and (0.155±0.017) h, (0.803±0.046) and (2.233±0.410) h, (0.016±0) and (0.149±0.018) L·h⁻¹·kg⁻¹, (0.015±0.001) and (0.446±0.016) L·h⁻¹·kg⁻¹, (133.335±3.844) and (9.298±0.179) mg·h·L⁻¹, (143.851±3.595) and (14.464±1.451) mg·h·L⁻¹, (0.009±0.001) and (0.223±0.007) L·kg⁻¹, (0.006±0.001) and (0.212±0.032) L·kg⁻¹, respectively.",[Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902908/),,0.006,27226,DB00130,L-Glutamine
,14511565,whole body half-life,"Pharmacokinetic and biodistribution studies in mice demonstrated a relatively long whole body half-life of 32 h in vivo and significant intratumoral accretion, respectively.",Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14511565/),h,32,29451,DB00130,L-Glutamine
,582759,terminal half-life,"As a result, experimental data could have been fitted to a tri- or tetra-exponential equation, with terminal half-life of about 24 h.",Pharmacokinetic approach to proglumide long-term activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/582759/),h,24,31392,DB00130,L-Glutamine
,11595694,maximum tolerated dose,The maximum tolerated dose was 410 mg/kg/day for 5 days.,A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11595694/),mg,410,32413,DB00130,L-Glutamine
,11118821,Peak plasma glutamine concentrations,"Peak plasma glutamine concentrations were 42% higher than postabsorptive basal values when exogenous glutamine was administered in the form of free glutamine added to caseinate (925.9 +/- 67.7 versus 651.3 +/- 44.0 micromol/L, respectively).",Plasma glutamine response to enteral administration of glutamine in human volunteers (free glutamine versus protein-bound glutamine). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118821/),[μM] / [l],925.9,34681,DB00130,L-Glutamine
,11118821,Peak plasma glutamine concentrations,"Peak plasma glutamine concentrations were 42% higher than postabsorptive basal values when exogenous glutamine was administered in the form of free glutamine added to caseinate (925.9 +/- 67.7 versus 651.3 +/- 44.0 micromol/L, respectively).",Plasma glutamine response to enteral administration of glutamine in human volunteers (free glutamine versus protein-bound glutamine). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118821/),[μM] / [l],651.3,34682,DB00130,L-Glutamine
,8137283,Km,"Phenylacetate displayed nonlinear pharmacokinetics [Km = 105.1 +/- 44.5 (SD) microgram/ml, Vmax = 24.1 +/- 5.2 mg/kg/h and Vd = 19.2 +/- 3.3 L].",A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137283/),[μg] / [ml],105.1,34920,DB00130,L-Glutamine
,8137283,Vmax,"Phenylacetate displayed nonlinear pharmacokinetics [Km = 105.1 +/- 44.5 (SD) microgram/ml, Vmax = 24.1 +/- 5.2 mg/kg/h and Vd = 19.2 +/- 3.3 L].",A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137283/),[mg] / [h·kg],24.1,34921,DB00130,L-Glutamine
,8137283,Vd,"Phenylacetate displayed nonlinear pharmacokinetics [Km = 105.1 +/- 44.5 (SD) microgram/ml, Vmax = 24.1 +/- 5.2 mg/kg/h and Vd = 19.2 +/- 3.3 L].",A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137283/),l,19.2,34922,DB00130,L-Glutamine
,25625323,EC50,"In vitro cell toxicity experiments using two different CD30-positive cell lines (Karpas 299 and Raji-CD30(+)) revealed comparable EC50 values for ADCETRIS (1.8 ± 0.4 and 3.6 ± 0.6 ng/mL, respectively) and the four cAC10-based ADCs (2.0 ± 0.4 to 4.9 ± 1.0 ng/mL).",Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625323/),[ng] / [ml],1.8,38838,DB00130,L-Glutamine
,25625323,EC50,"In vitro cell toxicity experiments using two different CD30-positive cell lines (Karpas 299 and Raji-CD30(+)) revealed comparable EC50 values for ADCETRIS (1.8 ± 0.4 and 3.6 ± 0.6 ng/mL, respectively) and the four cAC10-based ADCs (2.0 ± 0.4 to 4.9 ± 1.0 ng/mL).",Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625323/),[ng] / [ml],3.6,38839,DB00130,L-Glutamine
,25625323,EC50,"In vitro cell toxicity experiments using two different CD30-positive cell lines (Karpas 299 and Raji-CD30(+)) revealed comparable EC50 values for ADCETRIS (1.8 ± 0.4 and 3.6 ± 0.6 ng/mL, respectively) and the four cAC10-based ADCs (2.0 ± 0.4 to 4.9 ± 1.0 ng/mL).",Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625323/),[ng] / [ml],2.0,38840,DB00130,L-Glutamine
,25625323,EC50,"In vitro cell toxicity experiments using two different CD30-positive cell lines (Karpas 299 and Raji-CD30(+)) revealed comparable EC50 values for ADCETRIS (1.8 ± 0.4 and 3.6 ± 0.6 ng/mL, respectively) and the four cAC10-based ADCs (2.0 ± 0.4 to 4.9 ± 1.0 ng/mL).",Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625323/),[ng] / [ml],4.9,38841,DB00130,L-Glutamine
,25625323,tumor uptake,"The chemo-enzymatically conjugated, radioiodinated ADC showed higher tumor uptake (17.84 ± 2.2% ID/g 24 h p.i.) than (125)I-ADCETRIS (10.5 ± 1.8% ID/g 24 h p.i.).",Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625323/),[%·id] / [g],17.84,38842,DB00130,L-Glutamine
,25625323,tumor uptake,"The chemo-enzymatically conjugated, radioiodinated ADC showed higher tumor uptake (17.84 ± 2.2% ID/g 24 h p.i.) than (125)I-ADCETRIS (10.5 ± 1.8% ID/g 24 h p.i.).",Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625323/),[%·id] / [g],10.5,38843,DB00130,L-Glutamine
,18331613,to peak concentrations,"The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001).",The citrulline generation test: proposal for a new enterocyte function test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],0.,40669,DB00130,L-Glutamine
,18331613,to peak concentrations,"The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001).",The citrulline generation test: proposal for a new enterocyte function test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],0.13,40670,DB00130,L-Glutamine
,18331613,to peak concentrations,"The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001).",The citrulline generation test: proposal for a new enterocyte function test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],0.09,40671,DB00130,L-Glutamine
,18331613,iAUC T90,"The iAUC T90 was 447 +/- 179 and 1039 +/- 178 micromol/L/min in non-adapted and adapted SBS, respectively (P = 0.04).",The citrulline generation test: proposal for a new enterocyte function test. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],447,40672,DB00130,L-Glutamine
,18331613,iAUC T90,"The iAUC T90 was 447 +/- 179 and 1039 +/- 178 micromol/L/min in non-adapted and adapted SBS, respectively (P = 0.04).",The citrulline generation test: proposal for a new enterocyte function test. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],1039,40673,DB00130,L-Glutamine
,11534935,glucose-to-lipids ratio,Eight healthy volunteers received peripheral PN for 10 h providing 10.5 mg N x kg(-1) x h(-1) and 2.0 kcal x kg(-1) x h(-1) (glucose-to-lipids ratio: 70/30%).,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,70,60120,DB00130,L-Glutamine
,11534935,glucose-to-lipids ratio,Eight healthy volunteers received peripheral PN for 10 h providing 10.5 mg N x kg(-1) x h(-1) and 2.0 kcal x kg(-1) x h(-1) (glucose-to-lipids ratio: 70/30%).,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,30,60121,DB00130,L-Glutamine
,11534935,DeltaN,DeltaN was: 0.8+/-0.5 gN/10 h.,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[gn] / [10·h],0.8,60122,DB00130,L-Glutamine
<,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],0.5,60123,DB00130,L-Glutamine
<,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],1.5,60124,DB00130,L-Glutamine
>,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,99,60125,DB00130,L-Glutamine
>,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,99,60126,DB00130,L-Glutamine
<,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],0.6,60127,DB00130,L-Glutamine
,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],2.8,60128,DB00130,L-Glutamine
<,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],3,60129,DB00130,L-Glutamine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],6.8,60130,DB00130,L-Glutamine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],8.2,60131,DB00130,L-Glutamine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],8.8,60132,DB00130,L-Glutamine
>,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,98,60133,DB00130,L-Glutamine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,95,60134,DB00130,L-Glutamine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60135,DB00130,L-Glutamine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60136,DB00130,L-Glutamine
>,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,97,60137,DB00130,L-Glutamine
,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60138,DB00130,L-Glutamine
,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,95,60139,DB00130,L-Glutamine
greater,18805963,trough serum activities,The trough serum activities were greater than the desired threshold of 100 U/L in both treatment groups.,"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18805963/),[u] / [l],100,62889,DB00130,L-Glutamine
,15876422,half-life,Mono(diethylphosphoryl) obidoxime (DEP-obidoxime) was isolated for the first time showing remarkable stability under physiological conditions (half-life 13.5min; pH 7.1; 37 degrees C).,"Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876422/),min,13.5,81851,DB00130,L-Glutamine
,15876422,half-life,"The half-life was considerably extended to 20h at 0 degrees C, which facilitated the preparation and allowed isolation by HPLC.","Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876422/),h,20,81852,DB00130,L-Glutamine
,15876422,second-order rate constant,DEP-Obidoxime was an extremely potent inhibitor of human acetylcholinesterase approaching a second-order rate constant of 10(9)M(-1)min(-1) (pH 7.4; 37 degrees C).,"Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876422/),1/[M],10(9),81853,DB00130,L-Glutamine
,28302764,half maximal inhibitory concentration,The half maximal inhibitory concentration of 18F-GP1 to GPIIb/IIIa was 20 nM.,"18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302764/),nM,20,87536,DB00130,L-Glutamine
,28302764,clot-to-blood ratio,18F-GP1 bound to thrombi with a mean clot-to-blood ratio of 95.,"18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302764/),,95,87537,DB00130,L-Glutamine
,3099249,maximum increase,"Alanine caused hyperammonemia: maximum increase 107, 28-411 microM (geometric mean, 95% confidence interval); ammonia increments were nearly identical after alanine + benzoate (60, 17-213 microM) and alanine + phenylacetate (79, 13-467 microM) (NS).",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),μM,107,94455,DB00130,L-Glutamine
,3099249,upper therapeutic plasma concentrations,"Transient toxicity (dizziness, nausea, vomiting) occurred in four patients at the end of combined infusions, and we suggest upper therapeutic plasma concentrations of 4.5 mM for benzoate and 3.5 mM for phenylacetate.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,4.5,94456,DB00130,L-Glutamine
,3099249,upper therapeutic plasma concentrations,"Transient toxicity (dizziness, nausea, vomiting) occurred in four patients at the end of combined infusions, and we suggest upper therapeutic plasma concentrations of 4.5 mM for benzoate and 3.5 mM for phenylacetate.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,3.5,94457,DB00130,L-Glutamine
,3099249,t1/2S,"Benzoate and phenylacetate then decreased following first-order kinetics with t1/2S of 273 and 254 min, respectively.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),min,273,94458,DB00130,L-Glutamine
,3099249,t1/2S,"Benzoate and phenylacetate then decreased following first-order kinetics with t1/2S of 273 and 254 min, respectively.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),min,254,94459,DB00130,L-Glutamine
,3099249,Maximal plasma hippurate,"Maximal plasma hippurate (0.24, 0.14-0.40 mM) was lower than maximal phenylacetylglutamine (0.48, 0.22-1.06 mM, p = 0.008).",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,0.24,94460,DB00130,L-Glutamine
,3099249,maximal,"Maximal plasma hippurate (0.24, 0.14-0.40 mM) was lower than maximal phenylacetylglutamine (0.48, 0.22-1.06 mM, p = 0.008).",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,0.48,94461,DB00130,L-Glutamine
,2378793,elimination half-life,"After cessation of the CCK-infusion, plasma CCK concentrations decreased rapidly to basal values within 12 min, and the elimination half-life during loxiglumide infusion (4.8 +/- 0.8 min) was not significantly different from that during saline infusion (4.2 +/- 1.0 min).",Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378793/),min,4.8,94768,DB00130,L-Glutamine
,2378793,elimination half-life,"After cessation of the CCK-infusion, plasma CCK concentrations decreased rapidly to basal values within 12 min, and the elimination half-life during loxiglumide infusion (4.8 +/- 0.8 min) was not significantly different from that during saline infusion (4.2 +/- 1.0 min).",Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378793/),min,4.2,94769,DB00130,L-Glutamine
,31993927,tumor-to-healthy brain region ratio,Orthotopic human glioma xenografts displayed PET image tumor-to-healthy brain region ratio of 3.6 and 4.8 while subcutaneously xenografted BT4C gliomas displayed (n = 12) a tumor-to-muscle (flank) ratio of 1.9 ± 0.7 (range 1.3-3.4).,"(2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31993927/),,3.6,97575,DB00130,L-Glutamine
,31993927,tumor-to-healthy brain region ratio,Orthotopic human glioma xenografts displayed PET image tumor-to-healthy brain region ratio of 3.6 and 4.8 while subcutaneously xenografted BT4C gliomas displayed (n = 12) a tumor-to-muscle (flank) ratio of 1.9 ± 0.7 (range 1.3-3.4).,"(2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31993927/),,4.8,97576,DB00130,L-Glutamine
,31993927,tumor-to-muscle (,Orthotopic human glioma xenografts displayed PET image tumor-to-healthy brain region ratio of 3.6 and 4.8 while subcutaneously xenografted BT4C gliomas displayed (n = 12) a tumor-to-muscle (flank) ratio of 1.9 ± 0.7 (range 1.3-3.4).,"(2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31993927/),,1.9,97577,DB00130,L-Glutamine
,31993927,flank) ratio,Orthotopic human glioma xenografts displayed PET image tumor-to-healthy brain region ratio of 3.6 and 4.8 while subcutaneously xenografted BT4C gliomas displayed (n = 12) a tumor-to-muscle (flank) ratio of 1.9 ± 0.7 (range 1.3-3.4).,"(2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31993927/),,1.9,97578,DB00130,L-Glutamine
,8767407,T1/2kle,"T1/2kle was 19.6 +/- 2.3 min, Cltot 2.9 +/- 0.4 ml/kg/bw/min and DS 76.4 +/- 3.8 ml/kg/bw for 90 min.",Human growth hormone kinetics in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767407/),min,19.6,99347,DB00130,L-Glutamine
,8767407,Cltot,"T1/2kle was 19.6 +/- 2.3 min, Cltot 2.9 +/- 0.4 ml/kg/bw/min and DS 76.4 +/- 3.8 ml/kg/bw for 90 min.",Human growth hormone kinetics in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767407/),[ml] / [bw·kg·min],2.9,99348,DB00130,L-Glutamine
,8767407,DS,"T1/2kle was 19.6 +/- 2.3 min, Cltot 2.9 +/- 0.4 ml/kg/bw/min and DS 76.4 +/- 3.8 ml/kg/bw for 90 min.",Human growth hormone kinetics in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767407/),[ml] / [bw·kg],76.4,99349,DB00130,L-Glutamine
,19015870,peak concentration,"Following both leucine and BCAA ingestion the peak concentration of leucine was similar at rest (524 +/- 46 and 530 +/- 29 nmol/ml, respectively) and similar after STS (398 +/- 43 and 387 +/- 46 nmol/ml, respectively) but the rest and STS concentrations differed from each other (P < 0.01-0.001).","Effect of strength training session on plasma amino acid concentration following oral ingestion of leucine, BCAAs or glutamine in men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015870/),[nM] / [ml],524,99516,DB00130,L-Glutamine
,19015870,peak concentration,"Following both leucine and BCAA ingestion the peak concentration of leucine was similar at rest (524 +/- 46 and 530 +/- 29 nmol/ml, respectively) and similar after STS (398 +/- 43 and 387 +/- 46 nmol/ml, respectively) but the rest and STS concentrations differed from each other (P < 0.01-0.001).","Effect of strength training session on plasma amino acid concentration following oral ingestion of leucine, BCAAs or glutamine in men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015870/),[nM] / [ml],530,99517,DB00130,L-Glutamine
,19015870,peak concentration,"Following both leucine and BCAA ingestion the peak concentration of leucine was similar at rest (524 +/- 46 and 530 +/- 29 nmol/ml, respectively) and similar after STS (398 +/- 43 and 387 +/- 46 nmol/ml, respectively) but the rest and STS concentrations differed from each other (P < 0.01-0.001).","Effect of strength training session on plasma amino acid concentration following oral ingestion of leucine, BCAAs or glutamine in men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015870/),[nM] / [ml],398,99518,DB00130,L-Glutamine
,19015870,peak concentration,"Following both leucine and BCAA ingestion the peak concentration of leucine was similar at rest (524 +/- 46 and 530 +/- 29 nmol/ml, respectively) and similar after STS (398 +/- 43 and 387 +/- 46 nmol/ml, respectively) but the rest and STS concentrations differed from each other (P < 0.01-0.001).","Effect of strength training session on plasma amino acid concentration following oral ingestion of leucine, BCAAs or glutamine in men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015870/),[nM] / [ml],387,99519,DB00130,L-Glutamine
,21456601,IC(50),The affinity of all radiopeptides was high with IC(50) values between 0.5 and 4.8 nM.,Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456601/),nM,0.5 and 4.8,107122,DB00130,L-Glutamine
,1903599,Km,Glutamine was nearly quantitatively absorbed over the 30-cm study segment; estimated Km and Vmax of glutamine absorption were 2.48 and 2.32 mmol/min over the 30-cm study segment.,Absorption and metabolic effects of enterally administered glutamine in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903599/),[mM] / [min],2.48,108961,DB00130,L-Glutamine
,1903599,Vmax,Glutamine was nearly quantitatively absorbed over the 30-cm study segment; estimated Km and Vmax of glutamine absorption were 2.48 and 2.32 mmol/min over the 30-cm study segment.,Absorption and metabolic effects of enterally administered glutamine in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903599/),[mM] / [min],2.32,108962,DB00130,L-Glutamine
,1903599,appearance rate (Ra),"Enteral glutamine administration induced 1) a dose-dependent increase in plasma glutamine level; 2) a rise in the plasma level and appearance rate (Ra) of alanine (from 191 +/- 42 to 213 +/- 51 mumols.kg-1.h-1, P less than 0.05, for 0 and 46.8-mmol/h glutamine infusion rates, respectively) and in plasma levels of glutamate, citrulline, aspartate, and urea; 3) a decline in plasma free fatty acid and glycerol levels; and 4) no change in leucine or glucose Ra.",Absorption and metabolic effects of enterally administered glutamine in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903599/),[mumols] / [h·kg],213,108963,DB00130,L-Glutamine
,21883186,AUC,"The AUC values of citrulline decreased in LPS rats [citrulline, control: 761 ± 67 and LPS: 508 ± 72 μmol min/mL (P = 0·02)].","Endotoxemia affects citrulline, arginine and glutamine bioavailability. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883186/),[min·μM] / [ml],761,110026,DB00130,L-Glutamine
,21883186,AUC,"The AUC values of citrulline decreased in LPS rats [citrulline, control: 761 ± 67 and LPS: 508 ± 72 μmol min/mL (P = 0·02)].","Endotoxemia affects citrulline, arginine and glutamine bioavailability. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883186/),[min·μM] / [ml],508,110027,DB00130,L-Glutamine
,10720166,Peak increments,Peak increments of plasma Gln concentration were 794+/-107 micromol/L (mean +/- SEM) after bolus intake of 20 g of Ala-Gln and 398+/-61 micromol/L after intermittent intake of the same cumulative dosage of the dipeptide (P<0.01).,The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720166/),[μM] / [l],794,120155,DB00130,L-Glutamine
,10720166,Peak increments,Peak increments of plasma Gln concentration were 794+/-107 micromol/L (mean +/- SEM) after bolus intake of 20 g of Ala-Gln and 398+/-61 micromol/L after intermittent intake of the same cumulative dosage of the dipeptide (P<0.01).,The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720166/),[μM] / [l],398,120156,DB00130,L-Glutamine
,22052726,flow-rate,"Chromatographic separation was achieved using an isocratic mobile (0.2% formic acid solution-acetonitrile, 20:80, v/v) at a flow-rate of 0.5 mL/min on an Atlantis dC₁₈ column maintained at 40 °C with a total run time of 4.0 min.","Development and validation of an LC-MS/MS-ESI method for the determination of lorglumide, a CCK-1 antagonist in mouse plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052726/),[ml] / [min],0.5,126067,DB00130,L-Glutamine
,22052726,total run time,"Chromatographic separation was achieved using an isocratic mobile (0.2% formic acid solution-acetonitrile, 20:80, v/v) at a flow-rate of 0.5 mL/min on an Atlantis dC₁₈ column maintained at 40 °C with a total run time of 4.0 min.","Development and validation of an LC-MS/MS-ESI method for the determination of lorglumide, a CCK-1 antagonist in mouse plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052726/),min,4.0,126068,DB00130,L-Glutamine
excess,3342470,maximum tolerated dose,"A maximum tolerated dose was not defined; however, the projected maximum tolerated dose appears to be in excess of 450 mg/m2.",Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342470/),[mg] / [m2],450,129935,DB00130,L-Glutamine
,3342470,t 1/2,"The drug is rapidly cleared from plasma (t 1/2 = 3 h), and its volume of distribution is approximately twice that of total body water in children.",Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342470/),h,3,129936,DB00130,L-Glutamine
,1437854,apparent distribution volume,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),l,33,132023,DB00130,L-Glutamine
,1437854,half-life,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),min,41,132024,DB00130,L-Glutamine
,1437854,total body clearance,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),[l] / [min],0.56,132025,DB00130,L-Glutamine
,1437854,renal clearance,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),[ml] / [min],36,132026,DB00130,L-Glutamine
,12879279,half-life,The half-life of PAA was 55+/-18 min at the 1.8 g/m2 dose and 77+/-22 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,55,135414,DB00130,L-Glutamine
,12879279,half-life,The half-life of PAA was 55+/-18 min at the 1.8 g/m2 dose and 77+/-22 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,77,135415,DB00130,L-Glutamine
,12879279,half-life,The half-life of PAG was 112+/-53 min at the 1.8 g/m2 dose and 135+/-75 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,112,135416,DB00130,L-Glutamine
,12879279,half-life,The half-life of PAG was 112+/-53 min at the 1.8 g/m2 dose and 135+/-75 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,135,135417,DB00130,L-Glutamine
,12879279,clearance,The clearance of PAA was 66+/-33 ml/min per m2 at the 1.8 g/m2 dose and 60+/-24 ml/min per m2 at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[ml] / [m2·min],66,135418,DB00130,L-Glutamine
,12879279,clearance,The clearance of PAA was 66+/-33 ml/min per m2 at the 1.8 g/m2 dose and 60+/-24 ml/min per m2 at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[ml] / [m2·min],60,135419,DB00130,L-Glutamine
,12879279,Vm,"The Michaelis-Menten constants describing the conversion of PAA to PAG in the model (Vm and Km) were (means+/-SD) 18.4+/-13.8 mg/m2 per min and 152+/-155 microg/ml, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[mg] / [m2·min],18.4,135420,DB00130,L-Glutamine
,12879279,Km,"The Michaelis-Menten constants describing the conversion of PAA to PAG in the model (Vm and Km) were (means+/-SD) 18.4+/-13.8 mg/m2 per min and 152+/-155 microg/ml, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[μg] / [ml],152,135421,DB00130,L-Glutamine
,12879279,V(d-PAA),"The volumes of distribution for PAA and PAG (V(d-PAA) and V(d-PAG)) were 7.9+/-3.4 l/m2 and 34.4+/-16.1 l/m2, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[l] / [m2],7.9,135422,DB00130,L-Glutamine
,12879279,V(d-PA,"The volumes of distribution for PAA and PAG (V(d-PAA) and V(d-PAG)) were 7.9+/-3.4 l/m2 and 34.4+/-16.1 l/m2, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[l] / [m2],7.9,135423,DB00130,L-Glutamine
,12879279,V(d-PA,"The volumes of distribution for PAA and PAG (V(d-PAA) and V(d-PAG)) were 7.9+/-3.4 l/m2 and 34.4+/-16.1 l/m2, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[l] / [m2],34.4,135424,DB00130,L-Glutamine
,12879279,first-order elimination rate constant,The first-order elimination rate constant for PAG (k(e-PAG)) was 0.0091+/-0.0039 min(-1).,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),1/[min],0.0091,135425,DB00130,L-Glutamine
above,11218239,Holman index,"Only 1 of 8 patients, who did not receive parenteral lipids, had a Holman index above 0.2, indicative of EFA deficiency.","Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11218239/),,0.2,140016,DB00130,L-Glutamine
<,8329004,lag time,"The pharmacokinetics of fluoride in plasma is characterized by a short lag time (< 6 min), a rapid absorption, a peak which is reached 0.5-1.0 h after administration, followed by a biphasic elimination.",Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329004/),min,6,145433,DB00130,L-Glutamine
,8329004,k alpha,The first phase with a k alpha of 1.8 h-1 is followed by a slower phase with a K beta of 0.14 h-1.,Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329004/),1/[h],1.8,145434,DB00130,L-Glutamine
,8329004,K beta,The first phase with a k alpha of 1.8 h-1 is followed by a slower phase with a K beta of 0.14 h-1.,Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329004/),1/[h],0.14,145435,DB00130,L-Glutamine
,8329004,terminal elimination rate,"Probably the terminal elimination rate is slower, about 0.05 h-1.",Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329004/),1/[h],0.05,145436,DB00130,L-Glutamine
,17695416,half-life of elimination,PK-PD analyses of ERW in a few patients yielded an average half-life of elimination of 15.8+/-1.64 hours.,Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17695416/),h,15.8,147385,DB00130,L-Glutamine
,3415715,lag time,"After oral administration loxiglumide appeared in plasma with a lag time of 14 min, reached the peak 34 min after administration, being eliminated with an initial fast and a terminal slow elimination rate.",Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3415715/),min,14,149085,DB00130,L-Glutamine
,3120689,urinary excretion,The urinary excretion of the 5 dipeptides during parenteral nutrition ranged between 1 and 2% of the amount infused.,Parenteral nutrition with an amino acid solution containing a mixture of dipeptides. Evidence for efficient utilization of dipeptides in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120689/),%,1 and 2,149134,DB00130,L-Glutamine
,7647480,total serum clearance,"There was a 25% decrease in mean methotrexate total serum clearance in the GLN group compared with the control group (0.63 +/- 0.09 L.h-1.kg-1 and 0.47 +/- 0.13 L.h-1.kg-1, respectively, p = 0.01).",A significant methotrexate-glutamine pharmacokinetic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7647480/),[l] / [h·kg],0.63,150291,DB00130,L-Glutamine
,7647480,total serum clearance,"There was a 25% decrease in mean methotrexate total serum clearance in the GLN group compared with the control group (0.63 +/- 0.09 L.h-1.kg-1 and 0.47 +/- 0.13 L.h-1.kg-1, respectively, p = 0.01).",A significant methotrexate-glutamine pharmacokinetic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7647480/),[l] / [h·kg],0.47,150292,DB00130,L-Glutamine
,20698808,steady-state c,"Mean pre-dose steady-state creatine plasma concentrations were 20.3, 39.3, and 61.5 ug/ml at 5, 10, and 15 g b.i.d., respectively.","A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20698808/),[ug] / [ml],20.3,150593,DB00130,L-Glutamine
,20698808,steady-state c,"Mean pre-dose steady-state creatine plasma concentrations were 20.3, 39.3, and 61.5 ug/ml at 5, 10, and 15 g b.i.d., respectively.","A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20698808/),[ug] / [ml],39.3,150594,DB00130,L-Glutamine
,20698808,steady-state c,"Mean pre-dose steady-state creatine plasma concentrations were 20.3, 39.3, and 61.5 ug/ml at 5, 10, and 15 g b.i.d., respectively.","A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20698808/),[ug] / [ml],61.5,150595,DB00130,L-Glutamine
,21958546,IC(50),"Compound 28 (RO0509347) demonstrated potent GFAT inhibition (IC(50)=1μM) with a desirable pharmacokinetic profile in rats, and showed significant efficacy in reducing the glucose excursion in an OGTT test in ob/ob mice.","Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958546/),μM,1,151049,DB00130,L-Glutamine
,3896481,terminal (elimination-phase) half-life,"In 14 patients, the time course of plasma concentrations was characterized by a biexponential equation with a terminal (elimination-phase) half-life of 9.92 +/- 3.91 h (mean +/- SD), distribution phase half-life of 0.32 +/- 0.28 h, total body clearance of 1.69 +/- 0.48 liters/h/m2, and volume of distribution of 21.79 +/- 2.94 liters/m2.",Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896481/),h,9.92,153142,DB00130,L-Glutamine
,3896481,distribution phase half-life,"In 14 patients, the time course of plasma concentrations was characterized by a biexponential equation with a terminal (elimination-phase) half-life of 9.92 +/- 3.91 h (mean +/- SD), distribution phase half-life of 0.32 +/- 0.28 h, total body clearance of 1.69 +/- 0.48 liters/h/m2, and volume of distribution of 21.79 +/- 2.94 liters/m2.",Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896481/),h,0.32,153143,DB00130,L-Glutamine
,3896481,total body clearance,"In 14 patients, the time course of plasma concentrations was characterized by a biexponential equation with a terminal (elimination-phase) half-life of 9.92 +/- 3.91 h (mean +/- SD), distribution phase half-life of 0.32 +/- 0.28 h, total body clearance of 1.69 +/- 0.48 liters/h/m2, and volume of distribution of 21.79 +/- 2.94 liters/m2.",Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896481/),[l] / [h·m2],1.69,153144,DB00130,L-Glutamine
,3896481,volume of distribution,"In 14 patients, the time course of plasma concentrations was characterized by a biexponential equation with a terminal (elimination-phase) half-life of 9.92 +/- 3.91 h (mean +/- SD), distribution phase half-life of 0.32 +/- 0.28 h, total body clearance of 1.69 +/- 0.48 liters/h/m2, and volume of distribution of 21.79 +/- 2.94 liters/m2.",Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896481/),[l] / [m2],21.79,153145,DB00130,L-Glutamine
,3896481,Urinary excretion,"Urinary excretion of intact acivicin in nine patients ranged from 2-42% in the first 24 h following administration; interpatient variability in urinary excretion was large, but daily urinary recovery within patients on the daily x5 schedule was quite consistent.",Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896481/),%,2-42,153146,DB00130,L-Glutamine
,24771050,m/,Multiple reaction monitoring was used for quantification by monitoring ion transitions of m/z 275.3/172.1 for derivatized glutamine and 317.3/84.1 for internal standard in the electrospray positive ionization mode.,Rapid determination of glutamine in human plasma by high-performance liquid chromatographic-tandem mass spectrometry and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771050/),,275.3,153252,DB00130,L-Glutamine
,24771050,m/,Multiple reaction monitoring was used for quantification by monitoring ion transitions of m/z 275.3/172.1 for derivatized glutamine and 317.3/84.1 for internal standard in the electrospray positive ionization mode.,Rapid determination of glutamine in human plasma by high-performance liquid chromatographic-tandem mass spectrometry and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771050/),,172.1,153253,DB00130,L-Glutamine
,24771050,m/,Multiple reaction monitoring was used for quantification by monitoring ion transitions of m/z 275.3/172.1 for derivatized glutamine and 317.3/84.1 for internal standard in the electrospray positive ionization mode.,Rapid determination of glutamine in human plasma by high-performance liquid chromatographic-tandem mass spectrometry and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771050/),,317.3,153254,DB00130,L-Glutamine
,24177023,mean residence time,"After a bolus i.v. injection, the elimination of nor-NOHA was rapid (the mean residence time was 12.5 min).","Single- and multiple-dose pharmacokinetics of arginase inhibitor Nω-hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24177023/),min,12.5,154172,DB00130,L-Glutamine
,11489804,bioavailability,"The p.o. bioavailability of PB was 78% for all dose levels, and the biologically active concentration of 0.5 mM was achieved at all dose levels.",A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489804/),%,78,154293,DB00130,L-Glutamine
,2520335,amount of label recovered,"The amount of label recovered (in percent of injected dose) 3h after peptide bolus administration was 56% in CO2, 13% in muscle, 3.1% in liver, 1.9% in plasma, and 0.6% in kidney.",In vivo utilization of intravenously supplied L-alanyl-L-glutamine in various tissues of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520335/),%,56,157528,DB00130,L-Glutamine
,2520335,amount of label recovered,"The amount of label recovered (in percent of injected dose) 3h after peptide bolus administration was 56% in CO2, 13% in muscle, 3.1% in liver, 1.9% in plasma, and 0.6% in kidney.",In vivo utilization of intravenously supplied L-alanyl-L-glutamine in various tissues of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520335/),%,13,157529,DB00130,L-Glutamine
,2520335,amount of label recovered,"The amount of label recovered (in percent of injected dose) 3h after peptide bolus administration was 56% in CO2, 13% in muscle, 3.1% in liver, 1.9% in plasma, and 0.6% in kidney.",In vivo utilization of intravenously supplied L-alanyl-L-glutamine in various tissues of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520335/),%,3.1,157530,DB00130,L-Glutamine
,2520335,amount of label recovered,"The amount of label recovered (in percent of injected dose) 3h after peptide bolus administration was 56% in CO2, 13% in muscle, 3.1% in liver, 1.9% in plasma, and 0.6% in kidney.",In vivo utilization of intravenously supplied L-alanyl-L-glutamine in various tissues of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520335/),%,1.9,157531,DB00130,L-Glutamine
,2520335,amount of label recovered,"The amount of label recovered (in percent of injected dose) 3h after peptide bolus administration was 56% in CO2, 13% in muscle, 3.1% in liver, 1.9% in plasma, and 0.6% in kidney.",In vivo utilization of intravenously supplied L-alanyl-L-glutamine in various tissues of the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520335/),%,0.6,157532,DB00130,L-Glutamine
,12713684,half-life,"The results of these studies showed that compared with intact parental chTNT-3, which has a half-life of 134.2 h, the smaller derivatives were eliminated more rapidly (4.9-8.1 h).",Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12713684/),h,134.2,174757,DB00130,L-Glutamine
,19114888,differences,"Only the IED-fed patients showed an increase in plasma levels of GLN (differences [T90 - T0]: +40 +/- 6 vs. -35 +/- 18 micromol/L, mean +/- sem, p < 0.05, two-way analysis of variance), ARG (+35 +/- 5 vs.+1 +/- 4 micromol/L, p < 0.05), ornithine (+23 +/- 6 vs. -2 +/- 2 micromol/L, p < 0.05), and proline (+36 +/- 10 vs. -6 +/- 11 micromol/L, p < 0.05).",Increasing plasma glutamine in postoperative patients fed an arginine-rich immune-enhancing diet--a pharmacokinetic randomized controlled study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114888/),[μM] / [l],40,182806,DB00130,L-Glutamine
less,9313157,half-life times,Both amino acids were rapidly absorbed; half-life times were less than 20 min.,Effect of starch on the bioavailability of glutamine and leucine in the dairy cow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9313157/),min,20,184190,DB00130,L-Glutamine
,8354595,rate of relative bioavailability,"The mean index for the rate of relative bioavailability was, in fact, estimated to be 106.3 +/- 12.4%.",Pharmacokinetic study of the relative bioavailability and bioequivalence after oral intensive or repeated short term treatment with two polyamino acid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8354595/),%,106.3,185313,DB00130,L-Glutamine
,29404053,flow rate,"n-Hexane (containing 0.1% acetic acid) and ethanol (75:25, v/v) were used as mobile phase at a flow rate of 0.6 mL/min.",Separation and determination of acetyl-glutamine enantiomers by HPLC-MS and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404053/),[ml] / [min],0.6,186144,DB00130,L-Glutamine
higher,29404053,extraction recovery,The average extraction recovery was higher than 85% for both enantiomers at QC levels.,Separation and determination of acetyl-glutamine enantiomers by HPLC-MS and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404053/),%,85,186145,DB00130,L-Glutamine
,7650225,saturable elimination (Km,Phenylbutyrate achieved peak concentrations in the range of in vitro tumor activity (500-2000 mumol/L) and exhibited saturable elimination (Km = 34.1 +/- 18.1 micrograms/mL and Vmax = 18.1 +/- 18 mg/h/kg).,"Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650225/),[μg] / [ml],34.1,189842,DB00130,L-Glutamine
,7650225,Vmax,Phenylbutyrate achieved peak concentrations in the range of in vitro tumor activity (500-2000 mumol/L) and exhibited saturable elimination (Km = 34.1 +/- 18.1 micrograms/mL and Vmax = 18.1 +/- 18 mg/h/kg).,"Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650225/),[mg] / [h·kg],18.1,189843,DB00130,L-Glutamine
,7650225,times to maximum concentration,"Metabolism was rapid; the times to maximum concentration for phenylacetate and phenylacetylglutamine were 1 and 2 hours, respectively.","Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650225/),h,1,189844,DB00130,L-Glutamine
,7650225,times to maximum concentration,"Metabolism was rapid; the times to maximum concentration for phenylacetate and phenylacetylglutamine were 1 and 2 hours, respectively.","Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650225/),h,2,189845,DB00130,L-Glutamine
,10069350,steady-state plasma concentrations,"Mean steady-state plasma concentrations of phenylacetate and phenylacetylglutamine after escalation to the target doses of A10 and AS2-1 were 177+/-101 microg/mL and 302+/-102 microg/mL, respectively.",Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069350/),[μg] / [ml],177,190748,DB00130,L-Glutamine
,10069350,steady-state plasma concentrations,"Mean steady-state plasma concentrations of phenylacetate and phenylacetylglutamine after escalation to the target doses of A10 and AS2-1 were 177+/-101 microg/mL and 302+/-102 microg/mL, respectively.",Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069350/),[μg] / [ml],302,190749,DB00130,L-Glutamine
,27121790,Cmax,"Nine milliliters BID yielded similar lowering but was associated with more adverse events and higher phenylacetate (PAA) plasma concentrations (PAA Cmax of 144 [125] vs. 292 [224] µg/mL on 6 and 9 mL, respectively).",Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121790/),[μg] / [ml],144,198377,DB00130,L-Glutamine
,27121790,Cmax,"Nine milliliters BID yielded similar lowering but was associated with more adverse events and higher phenylacetate (PAA) plasma concentrations (PAA Cmax of 144 [125] vs. 292 [224] µg/mL on 6 and 9 mL, respectively).",Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121790/),[μg] / [ml],292,198378,DB00130,L-Glutamine
,19056578,peak concentrations,"Circulating GLP-1 concentrations increased in all study groups after glutamine ingestion, with peak concentrations at 30 min of 22.5 +/- 3.4, 17.9 +/- 1.1, and 17.3 +/- 3.4 pmol/L in LEAN, OB-CON, and OB-DIAB subjects, respectively.","Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19056578/),[pM] / [l],22.5,204701,DB00130,L-Glutamine
,19056578,peak concentrations,"Circulating GLP-1 concentrations increased in all study groups after glutamine ingestion, with peak concentrations at 30 min of 22.5 +/- 3.4, 17.9 +/- 1.1, and 17.3 +/- 3.4 pmol/L in LEAN, OB-CON, and OB-DIAB subjects, respectively.","Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19056578/),[pM] / [l],17.9,204702,DB00130,L-Glutamine
,19056578,peak concentrations,"Circulating GLP-1 concentrations increased in all study groups after glutamine ingestion, with peak concentrations at 30 min of 22.5 +/- 3.4, 17.9 +/- 1.1, and 17.3 +/- 3.4 pmol/L in LEAN, OB-CON, and OB-DIAB subjects, respectively.","Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19056578/),[pM] / [l],17.3,204703,DB00130,L-Glutamine
,24238262,tumour/background ratios (TBRs),In vivo tumour-to-background contrasts (tumour/background ratios (TBRs) of around 6) enabled identification of CCK2R-expressing tumours by both probes with low accumulation in CCK2R-negative tumours (TBR of around 2).,"Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238262/),,6,206772,DB00130,L-Glutamine
,24238262,TBR,In vivo tumour-to-background contrasts (tumour/background ratios (TBRs) of around 6) enabled identification of CCK2R-expressing tumours by both probes with low accumulation in CCK2R-negative tumours (TBR of around 2).,"Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238262/),,2,206773,DB00130,L-Glutamine
,6871883,Peak plasma levels,Peak plasma levels at the end of the 72-hr infusions correlated with dose and ranged from 0.09 to 1.10 microgram/ml.,Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6871883/),[μg] / [ml],0.09 to 1.10,212382,DB00130,L-Glutamine
,6871883,alpha-half-life,"When data from six patients were fitted to a two-compartment open model, alpha-half-life ranged from 1.1 to 63 mins, while beta-half-life ranged fro 338 to 629 mins.",Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6871883/),min,1.1 to 63,212383,DB00130,L-Glutamine
,6871883,beta-half-life,"When data from six patients were fitted to a two-compartment open model, alpha-half-life ranged from 1.1 to 63 mins, while beta-half-life ranged fro 338 to 629 mins.",Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6871883/),min,338 to 629,212384,DB00130,L-Glutamine
,6871883,Renal clearance,"Renal clearance ranged from 6 to 24 mL/min, and nonrenal clearance accounted for 58%-83% of the total drug clearance.",Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6871883/),[ml] / [min],6 to 24,212385,DB00130,L-Glutamine
,12843794,biologic half-life,"Pharmacokinetic and biodistribution studies in vivo showed that LEC/chTNT-3 had a biologic half-life of 3 hours and had good uptake in tumor (2.4% injected dose/g), which remained stable at 12 and 24 hours postinjection.",LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12843794/),h,3,220519,DB00130,L-Glutamine
,22961727,NH3 -AUC0-24hr,"Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control in the pivotal study, with mean (standard deviation, SD) NH3 -AUC0-24hr of 866 (661) versus 977 (865) μmol·h/L for glycerol phenylbutyrate and NaPBA, respectively.",Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961727/),[h·μM] / [l],866,221554,DB00130,L-Glutamine
,22961727,NH3 -AUC0-24hr,"Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control in the pivotal study, with mean (standard deviation, SD) NH3 -AUC0-24hr of 866 (661) versus 977 (865) μmol·h/L for glycerol phenylbutyrate and NaPBA, respectively.",Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961727/),[h·μM] / [l],977,221555,DB00130,L-Glutamine
,29230490,volume of distribution at steady state,The average tianeptine volume of distribution at steady state was 2.03 L/kg and the systemic clearance equaled 1.84 L/h/kg.,Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29230490/),[l] / [kg],2.03,221828,DB00130,L-Glutamine
,29230490,systemic clearance,The average tianeptine volume of distribution at steady state was 2.03 L/kg and the systemic clearance equaled 1.84 L/h/kg.,Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29230490/),[l] / [h·kg],1.84,221829,DB00130,L-Glutamine
,29230490,elimination half-lives,"The mean elimination half-lives of tianeptine and MC5 metabolite were 1.16 and 7.53 h, respectively.",Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29230490/),h,1.16,221830,DB00130,L-Glutamine
,29230490,elimination half-lives,"The mean elimination half-lives of tianeptine and MC5 metabolite were 1.16 and 7.53 h, respectively.",Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29230490/),h,7.53,221831,DB00130,L-Glutamine
,29230490,Bioavailability,Bioavailability of tianeptine after its intraperitoneal administration was 69%.,Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29230490/),%,69,221832,DB00130,L-Glutamine
,20382058,time-normalized AUC,"Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[μM] / [l],26.2,233490,DB00130,L-Glutamine
,20382058,time-normalized AUC,"Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[μM] / [l],38.4,233491,DB00130,L-Glutamine
,20382058,Cmax,"Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[μM] / [l],56.3,233492,DB00130,L-Glutamine
,20382058,Cmax,"Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[μM] / [l],79.1,233493,DB00130,L-Glutamine
,20382058,AUC(0-24),"Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[μgh] / [ml],540,233494,DB00130,L-Glutamine
,20382058,AUC(0-24),"Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[μgh] / [ml],739,233495,DB00130,L-Glutamine
,20382058,AUC(0-24),"Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[h·μg] / [ml],575,233496,DB00130,L-Glutamine
,20382058,AUC(0-24),"Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[h·μg] / [ml],596,233497,DB00130,L-Glutamine
,20382058,AUC(0-24),"Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[h·μg] / [ml],1098,233498,DB00130,L-Glutamine
,20382058,AUC(0-24),"Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar.","Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382058/),[h·μg] / [ml],1133,233499,DB00130,L-Glutamine
,16049639,half-life,"The half-life of the dipeptide was 0.26 hours (range, 0.15-0.63 h).",Elimination kinetics of L-alanyl-L-glutamine in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049639/),h,0.26,234963,DB00130,L-Glutamine
,9829740,plasma Css,"Pharmacokinetics studies performed in 15 patients revealed that the acivicin plasma Css increased from 0.44 microg/ml (range, 0.28-0.59 microg/ml) at the 25 mg/m2/day to 1.06 microg/ml (0.64-1.5 microg/ml) at the 50 mg/m2/dose level.",A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829740/),[μg] / [ml],0.44,241769,DB00130,L-Glutamine
,9829740,plasma Css,"Pharmacokinetics studies performed in 15 patients revealed that the acivicin plasma Css increased from 0.44 microg/ml (range, 0.28-0.59 microg/ml) at the 25 mg/m2/day to 1.06 microg/ml (0.64-1.5 microg/ml) at the 50 mg/m2/dose level.",A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829740/),[μg] / [ml],1.06,241770,DB00130,L-Glutamine
,17901164,RBC,"Regardless of treatment, RBC citrulline was lower than plasma citrulline, with an RBC-to-plasma ratio of 0.60 +/- 0.04, and urinary citrulline excretion accounted for <1% of the citrulline load filtered by kidney.",Manipulation of citrulline availability in humans. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17901164/),,0.60,245640,DB00130,L-Glutamine
,17901164,-to-plasma ratio,"Regardless of treatment, RBC citrulline was lower than plasma citrulline, with an RBC-to-plasma ratio of 0.60 +/- 0.04, and urinary citrulline excretion accounted for <1% of the citrulline load filtered by kidney.",Manipulation of citrulline availability in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17901164/),,0.60,245641,DB00130,L-Glutamine
,22575040,peak increases,"The corresponding mean peak increases were 179 ± 61, 284 ± 84, and 134 ± 36 μmol/L, respectively.",L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575040/),[μM] / [l],179,253397,DB00130,L-Glutamine
,22575040,peak increases,"The corresponding mean peak increases were 179 ± 61, 284 ± 84, and 134 ± 36 μmol/L, respectively.",L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575040/),[μM] / [l],284,253398,DB00130,L-Glutamine
,22575040,peak increases,"The corresponding mean peak increases were 179 ± 61, 284 ± 84, and 134 ± 36 μmol/L, respectively.",L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575040/),[μM] / [l],134,253399,DB00130,L-Glutamine
,22575040,areas under the plasma concentration curve,"Mean areas under the plasma concentration curve, calculated between 0 and 4 hours, were 127 ± 61, 284 ± 154, and 151 ± 63 μmol∙h∙",L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575040/),,127,253400,DB00130,L-Glutamine
,22575040,areas under the plasma concentration curve,"Mean areas under the plasma concentration curve, calculated between 0 and 4 hours, were 127 ± 61, 284 ± 154, and 151 ± 63 μmol∙h∙",L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575040/),,284,253401,DB00130,L-Glutamine
,22575040,areas under the plasma concentration curve,"Mean areas under the plasma concentration curve, calculated between 0 and 4 hours, were 127 ± 61, 284 ± 154, and 151 ± 63 μmol∙h∙",L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22575040/),,151,253402,DB00130,L-Glutamine
,32425776,flow rate,"The mobile phase was acetonitrile-water (70:30, v/v) containing 5 mM ammonium acetate and the flow rate was 0.3 ml/min.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),[ml] / [min],0.3,271396,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,189.1,271397,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,130.0,271398,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,148.0,271399,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,84.1,271400,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,104,271401,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,87.1,271402,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,191.0,271403,DB00130,L-Glutamine
,32425776,m/z,"Based on the multiple reaction monitoring (MRM) mode of positive ion, the precursors of product ions chosen for NAG, Glu, GABA, and N-carbamyl-L-glutamic (NCG, IS) were (m/z) 189.1→130.0, 148.0→84.1, 104→87.1, and 191.0→130.1, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),,130.1,271404,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,13.99,271405,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,27.43,271406,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,34.81,271407,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,31.37,271408,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,11.04,271409,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,59.07,271410,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,21.69,271411,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,2.69,271412,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,212.88,271413,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,234.92,271414,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,157.59,271415,DB00130,L-Glutamine
,32425776,drug distribution coefficients,"The drug distribution coefficients of NAG, Glu, GABA in brain and blood at low, medium, high doses of NAG and GHI groups were 13.99, 27.43, 34.81, 31.37; 11.04, 59.07, 21.69, 2.69%; 212.88, 234.92, 157.59, and 102.65%, respectively.",A Study on Acetylglutamine Pharmacokinetics in Rat Blood and Brain Based on Liquid Chromatography-Tandem Mass Spectrometry and Microdialysis Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32425776/),%,102.65,271416,DB00130,L-Glutamine
